At Immunotherapy and Melanoma Bridge meeting we interviewed Paolo Ascierto (Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute “Fondazione G. Pascale”, Naples, Italy) and Claus Garbe (Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany). Which role for target therapies, from metastatic to adjuvant setting? What about the next generation of treatment with target + immunotherapy?